#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis

Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines

Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists (AACE), released new recommendations for diabetes treatment in December 2016. They include information on the reduction of cardiovascular mortality in diabetics treated with empagliflozin (Jardiance).
Source: Diabetes 14. 2. 2020

News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics

Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency

Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
Source: Deficiency of Alpha-1-Antitrypsin 12. 1. 2022

News Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP

Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous immunoglobulins, platelet transfusions, etc.) can be used to quickly increase platelet count, but the response may not always be straightforward. Recently, reports have been published regarding the use of thrombopoietin receptor agonists (TPO-RAs) specifically aimed at rapidly increasing platelet count. The use of romiplostim in patients with ITP and intracranial hemorrhage is illustrated by the following case studies.
Source: Immune Thrombocytopenia 10. 8. 2022

News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.
Source: Intestinal Inflammations 21. 8. 2022

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs – sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) – in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.
Source: Cardiovascular Continuum 18. 11. 2021

News Emicizumab Changes the Lifestyle of Patients with Hemophilia A

At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of emicizumab on the lifestyle of people with hemophilia A.
Source: Quality Life Even with Hemophilia 30. 9. 2020

News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?

Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.
Source: Sartans in the Treatment of Hypertension 25. 5. 2023

News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’

The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.
Source: Chronic Heart Failure and Lipidology 9. 3. 2020

News Recent Advances in Physiotherapy for Hemophiliacs

Physiotherapy specifically focuses on movement and the movement potential of the individual, with the purpose of restoring or maintaining maximum mobility and functional abilities throughout life. Numerous experiences have shown that physiotherapeutic procedures hold a key position for patients with hemophilia.
Source: Hemophilia with Movement 28. 1. 2021

News Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors

Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.
Source: Non-Small Cell Lung Cancer 15. 2. 2021

News Perioperative Management of Bleeding in Patients with von Willebrand Disease Using Coagulation Factors

Von Willebrand disease is one of the most common congenital bleeding disorders. It is a heterogeneous group of diseases with varying severity of clinical manifestations. Some patients require pharmacological prevention or treatment of bleeding as part of perioperative care. The administration of concentrates containing coagulation factors is currently the gold standard for certain types of von Willebrand disease.
Source: Von Willebrand Disease 16. 12. 2020

News If Suicides Were COVID-19... or Why We Still Overlook a Significant Cause of Premature Deaths?

More than a year since the start of the pandemic, the SARS-CoV-2 coronavirus has claimed 2.8 million lives globally, with 127 million recorded cases of COVID-19 (as of March 29, 2021). According to World Health Organization (WHO) data, there are 800,000 suicides annually, with suicide attempts being up to 20 times more frequent, totaling over 16 million. Given our current focus on physical health, are we overlooking the extent and importance of mental health issues in the population? This question has been raised by several experts from different countries in their submission to the February issue of The Journal of Clinical Psychiatry.
Source: Depression and Anxiety 30. 3. 2021

News Evaluation of Various VWF Concentrates Regarding Their Ability to Mediate Platelet Binding to Collagen

The study by London researchers on various VWF concentrates focused, among other things, on evaluating their ability to mediate platelet binding to collagen.
Source: Von Willebrand Disease 27. 8. 2020

News Is Baricitinib Suitable for Long-Term Treatment of Rheumatoid Arthritis?

The nature of rheumatoid arthritis requires effective and long-term treatment. The current analysis of data from the long-term extension RA-BEYOND reveals the potential of baricitinib in maintaining low disease activity and remission with long-term use.
Source: Biological Treatment 12. 3. 2021

News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab

During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.
Source: Quality Life Even with Hemophilia 3. 8. 2020

News The Role of Probiotics in the Prevention of Childhood Infections

Although common acute respiratory and gastrointestinal infections are a part of childhood, they pose a significant burden on families and the healthcare and social care system. An unexpected role in their prevention can be played by the gut microbiome, specifically its support through certain probiotics. However, it is necessary to choose products supported by clinical studies.
Source: GI, colic and microbiome 11. 2. 2020

News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma

Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.
Source: Hematologic Malignancies 4. 1. 2022

News Targeted Treatment of Metastatic Breast Cancer in the 2nd Line – Experiences from Practice

The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves dual blockade of the HER2 signaling pathway using trastuzumab and pertuzumab in combination with a taxane cytostatic. After the failure of this therapy, treatment with trastuzumab emtansine (T-DM1) is recommended. However, this recommendation is not supported by a prospectively designed controlled study examining the outcomes of this therapeutic sequence. Therefore, a group of Italian authors decided to publish the results of a patient cohort treated with this sequence in real clinical practice conditions.
Source: Breast Carcinoma 23. 11. 2020

News Inflammation, Polyunsaturated Fatty Acids and Their Significance in the Development and Treatment of Depression

Depression is currently a highly discussed disease with a prevalence that is likely to rise. Therefore, scientists are focusing on potential causes and new treatment modalities. It has been shown that inflammation, which can be influenced by polyunsaturated fatty acids, likely plays a role in the development of the disease. Inflammation is also a possible explanation for the frequent coexistence of depression and metabolic syndrome.
Source: Depression and Anxiety 19. 7. 2020

News Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?

SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new perspective on the treatment of heart failure.
Source: Modern Treatment of Diabetes 19. 2. 2020

News Physiological and Clinical Effect of Romiplostim in the Treatment of ITP

Romiplostim in the treatment of immune thrombocytopenia (ITP) has demonstrated safety and the promise of long-term remission, enabling many pediatric and adult patients to discontinue treatment and maintain a drug-free state.
Source: Immune Thrombocytopenia 11. 10. 2021

News Could candesartan counteract adverse intestinal changes induced by hypertension?

An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the composition of the microflora. It expands the knowledge of recently described pathophysiological changes in the gut associated with hypertension.
Source: Sartans in the Treatment of Hypertension 6. 3. 2020

News INFOGRAPHIC: How does liposomal ozonized oil work in treating eye infections?

Ozonized sunflower oil exhibits antimicrobial, anti-inflammatory, and healing properties, which is why it is added to eye drops intended for infection prevention. We bring you a clear schematic of the mechanism of action of liposomal ozonized oil.
Source: Treatment of Glaucoma 24. 3. 2023

1 12 13 14 15 16 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#